论文部分内容阅读
目的:应用倾向性评分方法分析脉血康胶囊对冠心病治疗结局的影响。方法:基于22家三级甲等医院的电子医疗病历数据库，对使用和未使用脉血康胶囊的冠心病患者按照标准进行1∶1匹配。匹配后使用脉血康胶囊患者组(A组)与未使用脉血康胶囊(B组)均为2 464例。将数据库中治疗结局为“痊愈”和“好转”的重新合并定义为治疗有效，将“无效”、“死亡”和“其他”合并为治疗无效人群，应用倾向性评分方法对重新合并后两组的治疗结局有效性进行比较。结果:χn 2检验结果显示，在未控制混杂因素的情况下，两组的有效率比较差异有统计学意义(n P<0.05)，A组较B组治疗效果好。为进一步观察两组患者疗效的差别，分别通过三种logistic回归分析方法进行分析，均显示回归系数大于0，且差异均有统计学意义(n P<0.01)。n 结论:使用脉血康胶囊的冠心病患者较不使用该药的冠心病患者的治疗有效率高，脉血康胶囊可提高冠心病的临床疗效。“,”Objective:To analyze the effect of Maixuekang Capsule on the treatment outcome of coronary heart disease (CHD) by propensity score.Methods:Based on the electronic medical record database of 22 large-scale tertiary hospitals nationwide, this study matched the coronary heart disease patients using and not using Maixuekang capsule according to a certain standard (1∶1). After matching, there were 2 464 cases in the patients group (group A) and the patients group (group B). In the database, the recombination of “ recovery” and “ improvement” is defined as effective treatment, and “ invalid” , “ death” and “ other” are combined as ineffective treatment population. The effectiveness of the two groups after the re combination is compared by propensity score.Results:The results of χ n 2 test showed that the difference between the two groups was statistically significant (n P0, and there was statistical significance (n P<0.01).n Conclusions:The therapeutic effect of Maixuekang capsule on coronary heart disease is higher than that of patients without the drug.